Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

PTGX

Protagonist Therapeutics, Inc

Pharmaceutical Preparations · SIC 2834CIK 1377121Held by 5 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$46.0M
Net Income FY2025
$(130.0M)
EPS (Basic, as reported)
$-2.05
Net Margin FY2025
-282.8%
ROE FY2025
-21.2%
Total Equity
$615.0M
Shares Out
65M
Business description

Protagonist Therapeutics, Inc — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2014–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 20 → 46 +11% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue—203102927276043446
Research & development(26)(46)(59)(65)(75)(126)(126)(120)(138)(159)
General & administrative(7)(12)(14)(16)(19)(27)(32)(33)(43)(45)
Total operating expenses(33)(58)(73)(81)(93)(153)(158)(154)(182)(204)
Operating income(33)(38)(42)(81)(65)(126)(131)(94)253(158)
Interest expense———0(1)—————
Interest & investment income0133104152629
Other income (expense), net0000000000
Pre-tax income(37)(37)(40)(78)(65)(126)(127)(79)279(129)
Income tax expense00(1)(1)(1)000(4)(1)
Net income(37)(37)(39)(77)(66)(126)(127)(79)275(130)
EPS — basic————($1.92)($2.71)($2.60)($1.39)$4.47($2.05)
EPS — diluted————($1.92)($2.71)($2.60)($1.39)$4.23($2.05)
Shares outstanding — basic (M)————344649576264
Shares outstanding — diluted (M)————344649576564

Showing the latest 10 of 12 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.